Make 400% Profit
Selling your very own brand of High Quality CBD Products!

All Products Are
  • 0% THC
  • Non-GMO
  • Made in USA
  • No Pesticides
  • Your Brand
  • 400% Profit
  • Seed to Sale
  • 99.6% CBD
  • CO/2 Extract
  • 100% Organic

White/Private Label Program


Your Brand, Your Success

Apotheca Biosciences empowers your business with custom branding to give your CBD products an unique identity.

Apotheca Biosciences is a publicly traded company established in 2016. We have developed a custom line of CBD products and provide White/Private label for companies looking to create and launch their own brand of CBD products.

From seed to sale we can guarantee you will receive a product that is grown pesticide free and produced and manufactured in the USA. Apotheca Biosciences has established a strong relationship with the state of Kentucky and our partner farms. It was essential for Apotheca Biosciences to partner with the State of Kentucky due to the launch of their Industrial Hemp Pilot Program in 2014 under the supervision of the Kentucky Department of Agriculture. Kentucky is currently growing the highest quality hemp.

Apotheca Biosciences’ wholesale price and quality will give you the power to start your own brand of CBD products and increase your profit margin. All of our products are 100% guaranteed and backed by an inspection letter from the Kentucky Department of Agriculture as well as COA test results.

All of our CBD isolate is 100% organic, 0% THC, NON – GMO, made in the USA, no pesticides and laboratory tested. We use cutting-edge whole plant CO2 extraction to produce industry-leading CBD isolate that tests at 99.6%. Every single product is laser etched with date and batch number to ensure authenticity and quality.

We want to establish a long-lasting relationship with your company. Call us today to inquire about our wholesale pricing.

Call 888-633-2230
We will help you design your brand and help with any artwork needed…
We are here to help you launch your very own CBD brand!

No Comments

Comments are closed.